Colorectal cancer (CRR) is an important public health problem. More than 1 million people worldwide are newly diagnosed with colorectal cancer each year. Approximately half of these patients die of the disease, making colorectal cancer the second leading cause of cancer death in the world. According to the National Cancer Registry of Ukraine in 2012 the total number of colorectal cancers was 20 596 (44,4 cases per 100,000), men -9950 (43,4 %), women -10 631 (47,6 %). The total deaths due to colorectal cancer was 12 113 (above 50% of patients). Number of died among newly diagnosed during the first year was 68% in 2011. An analysis of CRC showed that 57% of patients had stage I-II, 20% -stage III and 12% of cases had stage IV. Thus, almost half of diagnoses were delayed. The human and financial costs of this disease have prompted considerable research efforts to evaluate the ability of screening tests to detect the colorectal cancer at an early curable stage. It is now established that screening by fecal occult blood test (FOBT) in average-risk populations can detect asymptomatic colorectal cancers and precancerous lesions (high-risk adenomas).
Results
To date, only the faecal occult blood test FOBT for men and women aged 50-74 years has been recommended by the EU for CRC screening. Among the available options, screening with guaiac-based faecal occult blood test was associated with a 11-21% CRC-mortality reduction in large, randomized studies. This mortality reduction resulted primarily from detection of early stage CRC. Although the guaiac-based test is effective in reducing colorectal cancer mortality and incidence, it is not optimal, and developing a simple and relatively inexpensive test for blood in stool that performs better would be beneficial. Immunochemical tests, which have not been evaluated in a randomized controlled trial, have performed at least as well and in some cases better and with generally higher compliance rates than guaiac-based tests.
Comparison of the guaiac-based and immunochemical FOBTs

Options gFOBT iFOBT
Procedure Samples of 3 consecutive bowel movements.
Sample of 1 bowel movement.
Mechanism of action
Detects the haem moiety of haemoglobin molecules by making use of the pseudoperoxidase activity of haem.
Uses monoclonal or polyclonal antibodies against human globin; does not rely on peroxidase.
Specific for human hemoglobin
Detects peroxidase in human blood as well as peroxidase in dietary constituents such as rare red meat and some fruit and vegetables. Guaiac tests are generally best at detecting large, more distal lesions.
Detects the globin moiety of human haemoglobin. The globin protein does not remain intact after passage through the upper gastrointestinal tracttherefore iFOBT is specific for bleeding in colon and rectum.
Dietary restrictions before test
These include dietary factors, for example animal haemoglobin/myoglobin in red meat, fruits and vegetables high in peroxidase activity, high doses of vitamin C, aspirin or other medication.
There are no restrictions in diet.
Analytical sensitivity 
Evidence of economic profitability FOBT-tests
Conclusions
We have reviewed the evidence about the quality, accessibility, and cost of screening using the FOBT to reduce colorectal cancer mortality. Fecal occult blood test screening benefits include reduction in CRR mortality, possible reduction in cancer incidence through detection and removal of colorectal adenomas and potentially, treatment of early colorectal cancers may involve less invasive surgery. Thus, implementation of biennial fecal occult blood test screening is an efficient use of health resources.
The main objective for the improvement of cancer patients' care is the introduction of national colorectal cancer screening programs based on evidence and available to people across the country. Introduction of clinical and cost-effectiveness screening methods in Ukraine and coordination of Ukrainian and world practices will provide timely and effective medical care for patients with CRR. In order to integrate these approaches into clinical practice based on evidence the clinical protocols are being developed. To critically re-evaluate the effectiveness and economic impact of screening in the US population.
Project of published outcomes from each of the three large randomized controlled trials of fecal occult blood testing to the US population, as if each clinical trial had been done in the population as a whole.
A fecal occult blood testing program would save 100 000 lives over 10 yr. Screening would incur total costs of $ 3-4 billion over 10 yr, or $ 2,500 per LYG. To assess the cost-effectiveness of screening for colorectal cancer using a fecal occult blood screening test in a cohort of 100 000 asymptomatic individuals 50-74 years of age.
A decision analysis model using a Markov approach simulates the trajectory of the cohort allocated either to screening or no screening over a 20-year period. Clinical and economic data came from the Burgundy trial, French population-based studies, and Registry data.
Modeling biennial screening versus the absence of screening over a 20-year period resulted in a 17,7 % mortality reduction and a discounted incremental cost-effectiveness ratio of 3357 € per LYG among individuals 50-74 years of age. To assess the consequences, costs, and costeffectiveness of CRC screening in average-risk individuals.
Cost-effectiveness analysis from a societal perspective using a Markov model.
The most effective strategy was annual rehydrated FOBT + sigmoidoscopy (followed by colonoscopy if either a low-or high-risk polyp was found) every 5 years from age 50 to 85 years, which resulted in a 60 % reduction in cancer incidence and an 80 % reduction in CRC mortality compared with no screening, and an ICER of $ 92 900 per LYG. To assess the barriers of screening, which include unproven efficacy of the procedure and high costs.
Cost analyses are derived from two mathematic models that estimate screening costs and effects based on expert opinion and data from uncontrolled screening studies. To apply a population-based method of medical decision making in the area of primary screening for CRC in order to illustrate a reduction in health care costs while increasing access and maintaining quality of care. Looking into the future, it is possible to increase screening rates from 50% to 100%, while saving almost $ 10 billion per decade by using FOBT for all eligible Americans. To examine the costs and cost-effectiveness of full implementation of biennial bowel cancer screening for Australian residents aged 50-74 years.
Identification of existing economic models from 1993 to 2010 through searches of PubMed and economic analysis databases, and by seeking expert advice; and additional modelling to determine the costs and costeffectiveness of full implementation of biennial FOBT Full implementation of biennial screening at a rough estimate is $ 150 million, which makes it possible to reduce mortality from CRC by 15 % -25 %, prevent 300-500 deaths from CRC and save lives annually 3600-6000 years Cost LYG $ 25 000 -$ 41 667 compared with the absence of screening The purpose of this analysis was to provide a model for comparing several colon screening programs and to determine the key variables that impact program effectiveness.
Five screening programs were compared: annual FOBT alone, flexible sigmoidoscopy, flexible sigmoidoscopy and FOBT combined, one-time colonoscopy, and air-contrast barium enema. Cost-effectiveness was defined as the cost per cancer death prevented.
FOBT alone is the most cost-effective of the programs. If the average cost of treating cancer is $ 25 000, the cost of screening for people over 10 years will be $ 677. If the cost of treatment of advanced cancer detected was $ 50 000, the cost of screening for people over 10 years does not exceed $ 1000.
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Li-Sheng Chen, Chao-Sheng Liao, Shu-Hui Chang, Hsin-Chih Lai and Tony HsiuHsi Chen. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 2007; 14:191-199 To determine the optimal cut-off of the immunochemical faecal occult blood test (iFOBT) by using costeffectiveness analysis.
Data were collected from screen-detected cases for the cut-off above 100 ng/mL and interval cancers were obtained from a nationwide cancer registry for a cut-off below 100 ng/mL. Formal economic evaluation was further applied to identifying the optimal cut-off by assessing the minimum ICER, an indicator for cost per LYG (effectiveness), given a series of cutoffs of iFOBT, ranging from 30 to 200 ng/mL compared with no screening.
In economic appraisal, the screening programme irrespective of any cut-off dominated (less cost and more effectiveness) over the control group. The optimal cut-off (the lowest ICER) was 110 ng/mL at which an average of 0,054 life year was gained and that of $ 950 was saved. Estimated the incremental cost-effectiveness of 10 strategies for colorectal cancer screening, as well as no screening, incorporating quality of life, noncompliance and data on the costs and benefits of chemotherapy.
Used a probabilistic Markov model to estimate the costs and qualityadjusted life expectancy of 50-year-old average-risk Canadians without screening and with screening by each test.
Low-sensitivity gFOBT, performed annually; iFOBT, performed annually; and colonoscopy, performed every 10 years. These strategies reduced the incidence of colorectal cancer by 44 %, 65 % and 81 %, and mortality by 55 %, 74 % and 83 %, respectively, compared with no screening. These strategies generated ICER of $ 9159, $ 611 and $ 6133 per QALY. To perform an economic evaluation of CRC screening in average risk North American individuals considering all relevant screening modalities and current CRC treatment costs.
An incremental cost-utility analysis using a Markov model was performed comparing guaiac-based fecal occult blood test (gFOBT) or fecal immunochemical test (iFOBT) annually, fecal DNA every 3 years, flexible sigmoidoscopy or computed tomographic colonography every 5 years, and colonoscopy every 10 years.
Annual FIT, assuming mid-range testing characteristics, was more effective and less costly compared to all strategies (including no screening) except iFOBT -high. Among the lifetimes of 100 000 averagerisk patients, the number of cancers could be reduced from 4 857 to 1 782 and the number of CRC deaths from 1 393 to 457, while saving CAN $ 68 per person. To assess the fecal immunochemical test (iFOBT) accuracy for colorectal cancer (CRC) and advanced neoplasia (AN) detection in CRC screening.
Multicentric, prospective, double blind study of diagnostic tests on asymptomatic average-risk individuals submitted to screening colonoscopy. Two stool samples were collected and the fecal hemoglobin concentration was determined in the first sample (iFOBT1) and the highest level of both samples (iFOBTmax) using the OC-sensor™.
At the best cut-off point for CRC detection (115 ng/mL), the NNS to detect a CRC were 10,2 and 15,8; and the cost per CRC was 1814 € and 2985 € on iFOBT1 and iFOBTmax strategies respectively. At this threshold the sensitivity, NNS and cost per AN detected were 30%, 1.76, and 306 €, in iFOBT1 strategy, and 36%, 2,26 € and 426 €, in iFOBTmax strategy, respectively.
Materials and methods
For the systematic review of the literature primary sources, meta-analyzes, systematic reviews, randomized cohort studies published between 1996 and 2013 were performed in the PubMed and DynaMed databases. Keywords: occult blood test; guaiacum test; immunochemical test, colorectal cancer screening, costeffectiveness, colorectal cancer mortality. Of the 687 sources only 46 met criteria.
Inclusion criteria:
• Patients with average-risk of CRC.
• All patients > 45 years.
• Patients had FOBT annually or every 2 years, followed by colonoscopy if the result was positive.
• The results of interest for us: mortality, sensitivity, specificity, predictive value, the costeffectiveness analysis, life-years gained.
Exclusion criteria:
• Studies with < 100 patients.
• Studies which don't include enough data for the analysis.
• Patients with high risk of CRC.
